Overview

Impact of Nesiritide on Early Postoperative Recovery After Total Cavo-Pulmonary Connection Surgery in Children

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
0
Participant gender:
All
Summary
Nesiritide, a recombinant human B-type natriuretic peptide, has favorable effects on patient symptoms, hemodynamics, and the neurohumoral profile in adults with decompensated congestive heart failure and in those recovering from cardiac surgery involving cardiopulmonary bypass. Investigators seek to determine whether nesiritide would improve the early postoperative course after total cavo-pulmonary connection surgery in children.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
China National Center for Cardiovascular Diseases
Collaborator:
Tibet Kang Zhe Pharmaceutical Technology Co., Ltd
Treatments:
Natriuretic Peptide, Brain
Criteria
Inclusion Criteria:

1. Elective general anesthesia down Fontan surgery patients, postoperative retention of
patients with thoracic drainage tube

2. Age ≤ 14 years old between hospitalized patients, men and women are not limited

3. Postoperative hospital stay> 7 days

4. Patients or guardians voluntarily signed informed consent

Exclusion Criteria:

1. Before the group had serious head trauma need hospitalization or brain surgery
patients

2. Who received organ transplants

3. Preoperative 48 hours application of recombinant B-type natriuretic peptide drugs

4. Preoperative cardiogenic shock or hypotension difficult to correct the patient

5. Preoperative patients with active arrhythmia

6. Preoperative serum creatinine> 1.5mg / dl or need dialysis patients

7. Preoperative liver dysfunction (glutamic oxalacetic transaminase /glutamic pyruvate
transaminase elevated normal high 3 times or more)

8. Failed Fontan patients requiring secondary surgery

9. Patients with allergic to Nesiritide

10. The researchers believe that should not participate in the entry of patients

11. 3 months before the trial participated in other clinical trials